Acute myeloid leukemia · 6 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
7+3d and Midostaurin Variant #01 | FLT3 | R 51 285 | 21d | — | 74.7 mo | 1 | R 51 285 PFS proxy | 1 |
7+3i Variant #01 | FLT3 | R 18 145 | 7d | — | 12.9 mo | 1 | R 18 145 PFS proxy | 2 |
7+3i and Quizartinib Variant #01 Partial | FLT3 | R 18 145 | 21d | — | 31.9 mo | 1 | R 18 145 PFS proxy | 1 |
7+3d and Quizartinib Variant #01 Partial | FLT3 | R 12 452 | 21d | — | 31.9 mo | 1 | R 12 452 PFS proxy | 1 |
DA 3+10 Variant #01 | FLT3 | R 11 640 | 10d | — | — | 1 | R 11 640 PFS proxy | 2 |
7+3d Variant #01 | FLT3 | R 6 538 | — | — | 15.1 mo | 2 | R 13 076 PFS proxy | 11 |
6 of 6 regimens shown